CN100409852C - 一种消结复肝中成药 - Google Patents
一种消结复肝中成药 Download PDFInfo
- Publication number
- CN100409852C CN100409852C CNB2005100423806A CN200510042380A CN100409852C CN 100409852 C CN100409852 C CN 100409852C CN B2005100423806 A CNB2005100423806 A CN B2005100423806A CN 200510042380 A CN200510042380 A CN 200510042380A CN 100409852 C CN100409852 C CN 100409852C
- Authority
- CN
- China
- Prior art keywords
- portions
- parts
- radix
- liver
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 17
- 230000036737 immune function Effects 0.000 title claims description 11
- 241000208340 Araliaceae Species 0.000 claims abstract description 15
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 15
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 15
- 235000008434 ginseng Nutrition 0.000 claims abstract description 15
- 244000153234 Hibiscus abelmoschus Species 0.000 claims abstract description 14
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 13
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 13
- 241000717739 Boswellia sacra Species 0.000 claims description 13
- 241001057584 Myrrha Species 0.000 claims description 13
- 210000000582 semen Anatomy 0.000 claims description 13
- 241001250596 Pleione Species 0.000 claims description 12
- 239000004863 Frankincense Substances 0.000 claims description 11
- 239000009636 Huang Qi Substances 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 6
- 244000179560 Prunella vulgaris Species 0.000 claims description 2
- 241000545442 Radix Species 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 abstract description 24
- 238000011282 treatment Methods 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 19
- 210000004369 blood Anatomy 0.000 abstract description 18
- 239000008280 blood Substances 0.000 abstract description 18
- 206010028980 Neoplasm Diseases 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 230000006870 function Effects 0.000 abstract description 9
- 238000002512 chemotherapy Methods 0.000 abstract description 7
- 230000001717 pathogenic effect Effects 0.000 abstract description 6
- 239000003053 toxin Substances 0.000 abstract description 4
- 238000001959 radiotherapy Methods 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 231100000765 toxin Toxicity 0.000 abstract description 3
- 230000000973 chemotherapeutic effect Effects 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 230000004069 differentiation Effects 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 241000031023 Amana edulis Species 0.000 abstract 1
- 241001407408 Berberis fortunei Species 0.000 abstract 1
- 244000306301 Caesalpinia sappan Species 0.000 abstract 1
- 235000015162 Caesalpinia sappan Nutrition 0.000 abstract 1
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 229920000175 Pistacia lentiscus Polymers 0.000 abstract 1
- 241000195974 Selaginella Species 0.000 abstract 1
- 235000007212 Verbena X moechina Moldenke Nutrition 0.000 abstract 1
- 240000001519 Verbena officinalis Species 0.000 abstract 1
- 235000001594 Verbena polystachya Kunth Nutrition 0.000 abstract 1
- 235000007200 Verbena x perriana Moldenke Nutrition 0.000 abstract 1
- 235000002270 Verbena x stuprosa Moldenke Nutrition 0.000 abstract 1
- 238000005054 agglomeration Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 239000003088 amphibian venom Substances 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 230000036528 appetite Effects 0.000 description 7
- 235000019789 appetite Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 208000019790 abdominal distention Diseases 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 206010030302 Oliguria Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000002558 medical inspection Methods 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 230000001314 paroxysmal effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000010341 ping gan Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000008509 shugan jianpi Substances 0.000 description 2
- 208000021865 skull neoplasm Diseases 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000008539 xiaoyao Substances 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000709715 Hepatovirus Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- OWDQPILTDJLGCN-QHRIQVFBSA-N Isosinomenine Chemical compound C1C2=CC=C(OC)C(O)=C2[C@@]23C=C(OC)C(=O)C[C@@H]3[C@H]1N(C)CC2 OWDQPILTDJLGCN-QHRIQVFBSA-N 0.000 description 1
- 206010024552 Lip dry Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000009916 Yoshida Sarcoma Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002115 aflatoxin B1 Substances 0.000 description 1
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 1
- 229930020125 aflatoxin-B1 Natural products 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000003814 hair luster Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- OWDQPILTDJLGCN-UHFFFAOYSA-N isosinomenine Natural products C1C2=CC=C(OC)C(O)=C2C23C=C(OC)C(=O)CC3C1N(C)CC2 OWDQPILTDJLGCN-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000012747 synergistic agent Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种消结复肝中成药,它含有麝香0.05-0.15份,蟾酥0.015-0.02份,参三七3-15份,乳香5-20份,没药5-20份,苏木3-15份,十大功劳叶5-25份,石上柏10-30份,山慈姑3-15份,人参2-25份,黄芪10-60份,夏枯草10-45份,马鞭草10-45份,薏苡仁10-50份,根据中医治病讲究整体观念的理论,实施辨证论治,以清热凉血、散瘀止血为主,从整体上调节、恢复、增强机体免疫系统的作用,在控制肿瘤不继续发展的情况下,针对肿瘤的内在病因进行化瘀解毒消肿,益气扶正培本,本发明还是一种有效的化疗增效剂,对化疗引起的白细胞下降有明显升高作用,可减少或降低手术治疗、放射治疗、化学治疗的副作用,增强放、化疗的疗效。
Description
技术领域
本发明涉及一种消结复肝中成药,适用于各种原因导致的中、晚期肝硬化,肝癌以及各种转移性肝癌;还适用于肝癌手术和放化疗后的配合治疗。
背景技术
肝病是目前世界上发病率较广的疾病之一,其危害对人体健康、社会发展影响很大,有关资料统计显示,目前在我国已有1.2亿乙肝病毒携带者,2000万人携带丙肝病毒,2000万人患慢性肝炎,全国患肝病或各种肝病毒携带者已达总人口的十分之一,每年因肝病死亡者约30万人,其中约50%为因各种原因所致的肝硬化、原发性肝癌等,肝病已成为医学界最难治愈的疾病之一。
发明内容
本发明的目的旨在利用中国传统的中医理论,提供一种根据肝病、肿瘤的内在病因进行清热解毒消肿、活血化瘀散结,从而达到根治目的的消结复肝中成药。
本发明的技术方案是:一种消结复肝中成药,它是由下述重量配比的原料制成的:麝香0.05-0.15份,蟾酥0.015-0.02份,参三七3-15份,乳香5-20份,没药5-20份,苏木3-15份,十大功劳叶5-25份,石上柏10-30份,山慈姑3-15份,人参2-25份,黄芪10-60份,夏枯草10-45份,马鞭草10-45份,薏苡仁10-50份。
上述原料的较好配比是:(按重量份)麝香0.08-0.12份,蟾酥0.015-0.02份,参三七5-10份,乳香10-15份,没药10-15份,苏木5-10份,十大功劳叶6-15份,石上柏15-20份,山慈姑5-10份,人参3-15份,黄芪10-30份,夏枯草10-30份,马鞭草10-30份,薏苡仁15-30份。
上述原料的最好配比是:(按重量份)麝香0.1份,蟾酥0.015份,参三七9份,乳香15份,没药15份,苏木9份,十大功劳叶10份,石上柏20份,山慈姑9份,人参15份,黄芪30份,夏枯草30份,马鞭草30份,薏苡仁25份。
上述各味中药的药理药性为:
麝香,辛温香散,通行十二经脉,具有开窍醒神,活血散结,消肿止痛的功能,近代临床用于治疗肿瘤有非常好的效果。
蟾酥,具有解毒、止痛、开窍的作用。对肝癌、胃癌、卵巢癌、S180、宫颈癌U14、白血病等都有抑制作用;还有抗辐射、增强机体单核吞噬细胞系统功能、升高白细胞的作用。与麝香、人参、十大功劳叶、黄芪配合增强对肝癌、白血病的抑制作用。
参三七,具有散瘀止血、消肿定痛的作用。与乳香、没药、苏木配合对离体肝癌细胞有直接的抑制或杀死作用。
乳香、没药、苏木皆为活血祛瘀药,具有疏通血脉,促使血行,消散瘀血的作用,常用于治疗瘀血阻滞所引起的多种疾病。
十大功劳叶,可清热补虚,止咳化痰,系清凉性滋养强壮药,在以艾氏腹水癌作体内抗癌的筛选试验中,发现其中所含成分异汉防己碱有很好的抗癌作用。
石上柏,具有清热解毒、抗癌作用。能显著延长肝癌实体型肿瘤小鼠的生存期。
山慈姑,具有清热解毒、消痈散结的作用。其主要成分秋水仙碱是一种抗癌活性物质,能抑制细胞核分裂,使停止于中期,有抗癌和抗辐射作用。
人参,具有补脾益肺,生津益血之功能,可大补元气,培正固本,扶正驱邪。现代研究表明,人参能刺激造血器官,使造血机能旺盛,能增强机体免疫力,促进免疫球蛋白、白细胞的生成,防止多种原因引起的白细胞下降,临床应用于癌症手术或化疗后,以本品做综合治疗,可以延长其存活期。
黄芪,可补气升阳,生血行滞,托疮生肌,利尿消肿,临床应用具有保护肝脏,防止肝糖元减少的作用。
夏枯草,具有清肝火、散郁结作用。夏枯草煎剂能抑制艾氏腹水癌及S180肿瘤的生长。
马鞭草,具有活血、通经、利水作用。体外试验发现有抑制肿瘤细胞的作用。
薏苡仁,具有利水渗湿、清肺排脓、健脾止泻的作用。从薏苡仁提取的中性油脂对动物艾氏腹水癌、S180、吉田肉瘤、子宫颈癌U14等有抑制作用。
肝病多因肝气郁结、肝胆郁热而导致肝脏疏泄功能失司,阴虚火旺,气滞而血瘀,本发明根据中医治病讲究整体观念的理论,实施辨证论治,以清热凉血、散瘀止血为主,从整体上调节、恢复、增强机体免疫系统的作用,在控制肿瘤不继续发展的情况下,针对肿瘤的内在病因进行化瘀解毒消肿,益气扶正培本。经临床试验证明,本品有显著抑制肝纤维化增生和致癌物质黄曲霉素B1的致癌作用,而且对体内肝癌细胞有明显的抑制作用,其抑制率高达93.5%以上;并可延长移植肿瘤动物的寿命;还有能够提高肿瘤患者的巨噬细胞吞噬功能;从中提取的蛋白质合成因子可改善机体的DNA等代谢,但不增加病变组织中的DNA等,从而限制肿瘤发展。本品还是一种有效的化疗增效剂,对化疗引起的白细胞下降有明显升高作用,还能增强柔红霉素和长春新碱杀伤白血病细胞的能力,可减少或降低手术治疗、放射治疗、化学治疗的副作用,增强放、化疗的疗效。
下面结合实施例及临床观察资料对本发明做详细地解释说明。
实施例1,取麝香0.05kg,蟾酥0.015kg,参三七3kg,乳香5kg,没药5kg份,苏木3kg,十大功劳叶5kg,石上柏10kg,山慈姑3kg,人参2kg,黄芪10kg,夏枯草10kg,马鞭草10kg,薏苡仁10kg,洗净,除杂,粉碎,过筛,按照中药常规制作工艺制成散剂,9g/包装即成。
实施例2,取麝香0.15kg,蟾酥0.02kg,参三七15kg,乳香20kg,没药20kg份,苏木15kg,十大功劳叶25kg,石上柏30kg,山慈姑15kg,人参25kg,黄芪60kg,夏枯草45kg,马鞭草45kg,薏苡仁50kg,洗净,除杂,粉碎,过筛,按照中药常规制作工艺制成散剂,9g/袋包装即成。
实施例3,取麝香0.08kg,蟾酥0.015kg,参三七5kg,乳香10kg,没药10kg份,苏木5kg,十大功劳叶6kg,石上柏15kg,山慈姑5kg,人参3kg,黄芪10kg,夏枯草10kg,马鞭草10kg,薏苡仁15kg,洗净,除杂,粉碎,过筛,按照中药常规制作工艺制成散剂,9g/袋包装即成。
实施例4,取麝香0.12kg,蟾酥0.02kg,参三七10kg,乳香15kg,没药15kg份,苏木10kg,十大功劳叶15kg,石上柏20kg,山慈姑10kg,人参15kg,黄芪30kg,夏枯草30kg,马鞭草30kg,薏苡仁30kg,洗净,除杂,粉碎,过筛,按照中药常规制作工艺制成散剂,9g/袋包装即成。
实施例5,取麝香0.1kg,蟾酥0.015kg,参三七9kg,乳香15kg,没药15kg份,苏木9kg,十大功劳叶10kg,石上柏20kg,山慈姑9kg,人参15kg,黄芪30kg,夏枯草30kg,马鞭草30kg,薏苡仁25kg,洗净,除杂,粉碎,过筛,按照中药常规制作工艺制成散剂,9g/袋包装即成。
临床疗效观察资料:
一、毒性试验:
本品以动物能耐受的最大浓度的药量(临床成人用量的80倍)一日内2次灌胃给予小白鼠,共100只,雌雄各半。给药后即刻观察动物反应,并连续观察3周,肝肾功能、心肌功能、红细胞、白血球、血红蛋白及心电图均未发现异常,动物体重增加,毛发光泽,活动及食欲均正常。又取大鼠分低剂量、中剂量、高剂量以成人剂量的5-30倍,每日灌胃给药1次,连续5个月给药。经对大鼠的心、肝、脾、肺、肾、胃、胰腺和脑组织进行病理学检查,结果未发现毒副反应,显示本品临床使用安全有效。
不良反应:少数患者服用本品后会有轻微头晕现象,是对药物的不适应所致,用药后休息半小时即可恢复正常。
二、实用治疗病例:
1、治疗对象:
主治肝硬化及肝癌患者,症见胁下痞块,胁肋隐痛、刺痛,腹胀纳少,倦怠乏力,恶心呕吐,发热烦渴,腹水,小便短赤,舌红,脉细弱等。
2、用量用法:
规格:每盒10袋,每袋9g,3盒1个疗程。
每日2次,早、晚各1袋,饭后半小时温水冲服。
禁忌:忌辛辣、油腻的食物;忌酒。孕妇禁用。
3、治疗效果:
经过本品治疗的肝癌、肝硬化65例,与对照组(给予手术后或服用氟尿嘧啶、丝裂霉素、多柔比星等西药,或逍遥散、平肝舒络丸、疏肝健脾丸、益肝膏等中成药治疗)65例比较,用药3个疗程后,治疗组的有效率为92.75%,与对照组的89.5%比较,差异无显著性意义;用药6个疗程后,治疗组的有效率为96.8%,对照组的有效率为72%,两组差异有显著性意义。
用药6疗程后复诊结果统计表:
基本治愈 | 显效 | 无效 | |
西药:氟尿嘧啶、丝裂霉素、多柔比星等 | 0 | 44 | 21 |
中成药:逍遥散、平肝舒络丸、疏肝健脾丸、益肝膏等 | 3 | 45 | 17 |
本发明中成药 | 10 | 53 | 2 |
其中:基本治愈——肝功正常,B超、CT检查肝脾恢复,食欲佳,病痛无,各种肝或肿瘤病症基本消失
显效——各种病症明显减轻,医学检查肝、脾、胆等有好转,肝功恢复近正常
无效——病情无好转迹象
4、病例:
李云建,男,46岁,淄博市大武镇人,1994年2月13日初诊。
医学检查,1994年2月7日到淄博中心医院腹部CT扫描(CT号17192),肝左上方叶占位病变,病理诊断结果AFP>400ug/L,诊断:肝癌。
临床症状:1993年12月在博山市做装修工,工作受阻,暴怒暴忧,常借酒消愁,胃脘胀痛,食欲不振,肌肉消瘦,面现黑气,小便短赤,在博山医院就医不见好转,发展至两肋胀痛,食减,四肢乏力,肝区出现肿块,阵发性剧痛,才回家到淄博市中心医院检查治疗,诊断肝癌后,患者及家属已丧失信心,只用半支莲合剂作安慰性治疗,经其同乡陈其生医师介绍,才至我处就诊。肝区肿块质硬,可触及多个结节,边缘不整,阵发性胀痛,唇焦舌黄黑无津,面色枯黄带黑,食少纳呆,动则气喘,脉弦结。中医辨证,怒则伤肝,郁而化火,酒助火热而成结毒。气滞血瘀发为积症,肝喜条达,立疏肝解郁,泻火排毒,化瘀消症之法。给予本发明消结复肝冲剂6盒,嘱咐家属督促其戒酒,忌辛辣、油腻,并让在家中修养。在药吃完后复诊,肿块缩小,疼痛减轻,食量增加。患者已见一线生机,信心增强,仍遵上法治疗。6个疗程后患者临床症状基本消失,饮食起居正常,体重比前增加十多斤,已能做轻体力劳动,肝肋下触及约一指位,无压痛。5月6日于淄博市人民医院B型超声切面显像报告,肝脾不大,肝左叶小结节、肿块已完全消失。为巩固疗效嘱咐再服2个疗程以善后。
周正国,男,67岁,山东省胶南市人。于1993年9月因肝区疼痛,食欲下降,消瘦,右侧头部生肿物,进济南千佛山医院住院检查治疗。住院号:065701。
1993年9月23日B型超声显像报告:肝内呈密集增粗分布欠均匀光点,尤以肝左叶、左内侧叶为甚,并见4.1×3.6cm光团,肝内实质性占位性病变。核磁共振扫描报告:右额部颞颅骨肿瘤。病理活体组织检验报告:右颞部,肝细胞癌转移。诊断:肝癌脑转移。因身体太虚弱不能接受化疗而出院回家,四处寻医问药至我处。初诊:面色枯黄,形体消瘦。右额颞部颅骨肿瘤已拳头大,脘腹胀痛,食少纳差,动则气喘,唇焦舌干苔薄黄,小便短赤,大便不通,脉弦洪。由于二十多年来情绪抑郁,暴忧,气滞血瘀,郁而化火,火毒凝结而成肝癌脑转移症。中医辨证患者因肝郁化火结毒,气滞血瘀痰凝。立疏肝解郁,活血祛瘀,泻火解毒法。处方:本发明消结复肝冲剂6盒。复诊,患者自觉症状改善,脘腹胀痛减轻,胃纳转佳,右额肿瘤明显消软。药已对症,仍遵上法治疗。半年后,肝区疼痛止,肝脏下未扪及肿块,右额肿瘤消软三分之二,饮食起居正常,满面笑颜,说话、思维、写字等反应动作灵敏,原有脑动脉硬化症也不药而愈。患者主诉,这也是他近10年来身体最佳时期。
王镇江,男,32岁。山东省东营市人。患乙肝四年,近一个月感觉乏力加重,伴腹胀,厌食,消瘦。在当地医院查肝功:谷丙转氨酶112单位,谷草转氨酶98单位。A/G:2.8/3.1。B超显示,肝大小正常。实质回声增强、脾大。诊为早期肝硬化。经服用本发明消结复肝冲剂1个月后复查,谷丙转氨酶40单位以下,谷草转氨酶45单位以下。A/G:2.6/1.9。B超显示,肝大小正常。实质回声前略增强、脾稍大。病情较前明显好转。继续服用半年后复查,各项指标均正常。
李云枫,男,44岁。山东省威海市人。患乙肝12年,曾服多种药物治疗。三年前在当地诊为肝硬化。来诊时消瘦,面色黯黑,乏力,轻微黄疸,肝区钝痛,厌食,柏油样黑便已三天。肝功异常。B超肝体积缩小,门静增宽,肝实质回声粗糙,脾肿大。A/G:1.6/3.2。服用本发明消结复肝冲剂1个月,症状明显好转。三个月后复查肝功能正常。A/G:2.7/2.3。继续治疗一年各项指标正常。随访两年未复发。
钱进发,男,67岁,山东省枣庄市人。患者于一年前突然腹部胀大,下肢浮肿,在当地住院治疗,当地医院确诊为“肝硬化晚期”。究其病史,患者于10余年前曾发现乙肝表现抗原阳性,但因肝功能正常,无明显自觉不适而未引起重视,并且长期饮酒。来诊时患者精神萎靡,面色黯黑、腹部膨隆如鼓,移动性浊音。经治疗一周腹水减退,三个月后自觉症状消失,已能参加轻体力劳动。间断服用本发明消结复肝冲剂至今已三年,病情稳定。
王栋梁,男,55岁。山东省高密市人。患乙肝二十余年,近五年反复出现腹水,呕血、黑便等症状。在当地住院治疗多次,病情时轻时重。1998年经人介绍求治于本院,来诊时患者已黑便三天,精神萎靡,消瘦,腹水量多,经服用本发明消结复肝冲剂治疗一个月后,精神转佳,黑便消失,体重上升5kg,腹水消失。坚持服用本发明冲剂已一年,病情稳定,无反复。
Claims (3)
1. 一种消结复肝中成药,它是由下述重量配比的原料制成的:麝香0.05-0.15份,蟾酥0.015-0.02份,参三七3-15份,乳香5-20份,没药5-20份,苏木3-15份,十大功劳叶5-25份,石上柏10-30份,山慈姑3-15份,人参2-25份,黄芪10-60份,夏枯草10-45份,马鞭草10-45份,薏苡仁10-50份。
2. 按照权利要求1所述的一种消结复肝中成药,它是由下述重量配比的原料制成的:麝香0.08-0.12份,蟾酥0.015-0.02份,参三七5-10份,乳香10-15份,没药10-15份,苏木5-10份,十大功劳叶6-15份,石上柏15-20份,山慈姑5-10份,人参3-15份,黄芪10-30份,夏枯草10-30份,马鞭草10-30份,薏苡仁15-30份。
3. 按照权利要求1所述的一种消结复肝中成药,它是由下述重量配比的原料制成的:麝香0.1份,蟾酥0.015份,参三七9份,乳香15份,没药15份,苏木9份,十大功劳叶10份,石上柏20份,山慈姑9份,人参15份,黄芪30份,夏枯草30份,马鞭草30份,薏苡仁25份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100423806A CN100409852C (zh) | 2005-01-22 | 2005-01-22 | 一种消结复肝中成药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100423806A CN100409852C (zh) | 2005-01-22 | 2005-01-22 | 一种消结复肝中成药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1679845A CN1679845A (zh) | 2005-10-12 |
CN100409852C true CN100409852C (zh) | 2008-08-13 |
Family
ID=35066851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100423806A Expired - Fee Related CN100409852C (zh) | 2005-01-22 | 2005-01-22 | 一种消结复肝中成药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100409852C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104001149A (zh) * | 2014-05-27 | 2014-08-27 | 刘存兵 | 一种治疗放射损伤中药组合物及其制备方法 |
CN112915172A (zh) * | 2021-04-27 | 2021-06-08 | 海南海府科技有限公司 | 一种用于提高人体免疫力的中药及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1058911A (zh) * | 1990-08-05 | 1992-02-26 | 陈江辉 | 化瘤净胶囊的配制方法 |
CN1080176A (zh) * | 1993-01-01 | 1994-01-05 | 浙江省中医院 | 薏苡仁中性油脂乳剂 |
CN1100944A (zh) * | 1993-12-31 | 1995-04-05 | 张校苏 | 治疗消化道系统肿瘤的中成药消癌灵 |
CN1113779A (zh) * | 1994-06-17 | 1995-12-27 | 殷广全 | 抗乙肝制剂 |
CN1171252A (zh) * | 1996-07-23 | 1998-01-28 | 林剑 | 中药抗癌制剂及其制备方法 |
CN1174065A (zh) * | 1997-07-16 | 1998-02-25 | 迟经惠 | 障碍贫血针剂 |
CN1298733A (zh) * | 1999-12-09 | 2001-06-13 | 殷增航 | 逐瘀生新散 |
-
2005
- 2005-01-22 CN CNB2005100423806A patent/CN100409852C/zh not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1058911A (zh) * | 1990-08-05 | 1992-02-26 | 陈江辉 | 化瘤净胶囊的配制方法 |
CN1080176A (zh) * | 1993-01-01 | 1994-01-05 | 浙江省中医院 | 薏苡仁中性油脂乳剂 |
CN1100944A (zh) * | 1993-12-31 | 1995-04-05 | 张校苏 | 治疗消化道系统肿瘤的中成药消癌灵 |
CN1113779A (zh) * | 1994-06-17 | 1995-12-27 | 殷广全 | 抗乙肝制剂 |
CN1171252A (zh) * | 1996-07-23 | 1998-01-28 | 林剑 | 中药抗癌制剂及其制备方法 |
CN1174065A (zh) * | 1997-07-16 | 1998-02-25 | 迟经惠 | 障碍贫血针剂 |
CN1298733A (zh) * | 1999-12-09 | 2001-06-13 | 殷增航 | 逐瘀生新散 |
Also Published As
Publication number | Publication date |
---|---|
CN1679845A (zh) | 2005-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102847064A (zh) | 抑制恶性肿瘤转移的中药 | |
CN102078569B (zh) | 一种治疗肝癌的中药制剂及其制备方法 | |
CN100372558C (zh) | 一种治疗肿瘤放、化疗后白细胞减少的药物 | |
CN101711848B (zh) | 一种辅助治疗肿瘤的中药组合物 | |
CN102688317B (zh) | 用于治疗肝癌的中药 | |
CN105535859A (zh) | 一种用于治疗胃癌的中药制剂及其制备方法 | |
CN101007159B (zh) | 防治肿瘤的中药 | |
CN103223149B (zh) | 一种治疗肺癌的中草药组合物 | |
CN100409852C (zh) | 一种消结复肝中成药 | |
CN110101820A (zh) | 一种用于治疗肥胖症的中药组合物 | |
CN103157062A (zh) | 一种治疗子宫肌瘤等妇科包块性疾病的药物组合物及其制备方法与应用 | |
CN103961506A (zh) | 中医调节性人体细胞免疫激动剂中药组合物 | |
CN103432401B (zh) | 治疗肺癌的中药三花五子六白散 | |
CN102228576B (zh) | 一种治疗盘状红斑狼疮的中成药 | |
CN105902951A (zh) | 联合化疗药治疗骨肉瘤的中药复方组合物 | |
CN104800675A (zh) | 用于治疗活动期溃疡性结肠炎的药物 | |
CN105435134A (zh) | 联合化疗药治疗胃癌的中药制剂 | |
CN100522237C (zh) | 一种抗癌软胶囊及其制备方法 | |
CN103893700A (zh) | 一种治疗乳腺癌的中药组合物 | |
CN101391074B (zh) | 一种治疗消化系肿瘤的药物组合物及其制备方法 | |
CN102362957B (zh) | 一种治疗深部红斑狼疮的中成药 | |
CN108853340A (zh) | 一种滋养肝肾的中药及其制备方法 | |
CN109260403A (zh) | 一种治疗胰腺癌的中药组合物 | |
CN106039194A (zh) | 一种治疗放、化疗引起白细胞减少的复合制剂 | |
CN105708989A (zh) | 一种用于治疗和改善心肌梗塞的药物制剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080813 Termination date: 20110122 |